The study of agents that selectively target histone deacetylases and cause transformed cell growth arrest, terminal differentiation, apoptosis, and cell death.
Lee JH, Choy ML, Ngo L, Venta-Perez G, Marks PA. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19629-34. doi: 10.1073/pnas.1117544108. Epub 2011 Nov 21.
Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6561-5. doi: 10.1073/pnas.1204429109. Epub 2012 Apr 9.
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999 Sep 9;401(6749):188-93.
Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000 Sep 15;60(18):5165-70.
Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007 Jan;25(1):84-90.
Biotechnology Achievement Award, Dart /NYU (2013)
Doctor of Science (hon. Caus.), Columbia University (2000)
Gold Medal for Distinguished Academic Accomplishments, Columbia University College of Physicians and Surgeons (1994)
President’s National Medal of Science (1991)
President’s Cancer Panel (1976-1979)
Council, National Academy of Sciences (1984-1987)
Discovery of SAHA (vorinostat)
Identification of HDAC6 specific inhibitor